[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TNSN07240A1 - Compounds for flaviviridae treatment - Google Patents

Compounds for flaviviridae treatment

Info

Publication number
TNSN07240A1
TNSN07240A1 TNP2007000240A TNSN07240A TNSN07240A1 TN SN07240 A1 TNSN07240 A1 TN SN07240A1 TN P2007000240 A TNP2007000240 A TN P2007000240A TN SN07240 A TNSN07240 A TN SN07240A TN SN07240 A1 TNSN07240 A1 TN SN07240A1
Authority
TN
Tunisia
Prior art keywords
flaviviridae
compounds
treatment
flaviviridae treatment
prevention
Prior art date
Application number
TNP2007000240A
Other languages
English (en)
Inventor
Beat Weidmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TNSN07240A1 publication Critical patent/TNSN07240A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2007000240A 2004-12-23 2007-06-22 Compounds for flaviviridae treatment TNSN07240A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63867604P 2004-12-23 2004-12-23
PCT/US2005/046058 WO2006071618A1 (fr) 2004-12-23 2005-12-20 Composes pour le traitement des infections virales par flaviviridae

Publications (1)

Publication Number Publication Date
TNSN07240A1 true TNSN07240A1 (en) 2008-11-21

Family

ID=36218613

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2007000240A TNSN07240A1 (en) 2004-12-23 2007-06-22 Compounds for flaviviridae treatment

Country Status (17)

Country Link
US (1) US20090214464A1 (fr)
EP (1) EP1830870A1 (fr)
JP (1) JP2008525458A (fr)
KR (1) KR20070089954A (fr)
CN (1) CN101084005A (fr)
AU (1) AU2005322241B2 (fr)
BR (1) BRPI0519355A2 (fr)
CA (1) CA2587586A1 (fr)
IL (1) IL183780A0 (fr)
MA (1) MA29097B1 (fr)
MX (1) MX2007007721A (fr)
NO (1) NO20073765L (fr)
NZ (1) NZ555142A (fr)
RU (1) RU2007128098A (fr)
TN (1) TNSN07240A1 (fr)
WO (1) WO2006071618A1 (fr)
ZA (1) ZA200703907B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
JP5322647B2 (ja) 2005-09-30 2013-10-23 スシネキス インク ウイルス感染の治療及び予防のためのシクロスポリンａのアリールアルキル及びヘテロアリールアルキル誘導体
EP1933859A2 (fr) 2005-09-30 2008-06-25 Scynexis, Inc. Procedes et compositions pharmaceutiques pour traiter et prevenir une infection par le virus de l'hepatite c
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2007136759A2 (fr) 2006-05-19 2007-11-29 Scynexis, Inc. Procédé de traitement et de prévention de troubles oculaires
WO2008069917A2 (fr) 2006-11-20 2008-06-12 Scynexis, Inc. Nouveaux peptides cycliques
CN102083852A (zh) 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
WO2010076329A1 (fr) 2008-12-31 2010-07-08 Scynexis, Inc. Dérivés de cyclosporine a
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2095926T5 (es) * 1990-11-02 2001-02-16 Novartis Ag Cyclosporins.
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
AU2001295966A1 (en) * 2000-10-19 2002-04-29 Fujisawa Pharmaceutical Co. Ltd. Cell damage inhibitor
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
WO2006038088A1 (fr) * 2004-10-01 2006-04-13 Debiopharm Sa Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine
NZ555143A (en) * 2004-12-23 2009-12-24 Novartis Ag Compositions for HCV treatment

Also Published As

Publication number Publication date
US20090214464A1 (en) 2009-08-27
AU2005322241B2 (en) 2010-02-18
AU2005322241A1 (en) 2006-07-06
BRPI0519355A2 (pt) 2009-01-20
EP1830870A1 (fr) 2007-09-12
KR20070089954A (ko) 2007-09-04
RU2007128098A (ru) 2009-01-27
NO20073765L (no) 2007-09-19
JP2008525458A (ja) 2008-07-17
ZA200703907B (en) 2009-08-26
CA2587586A1 (fr) 2006-07-06
WO2006071618A1 (fr) 2006-07-06
MA29097B1 (fr) 2007-12-03
NZ555142A (en) 2010-03-26
MX2007007721A (es) 2007-08-14
IL183780A0 (en) 2007-09-20
CN101084005A (zh) 2007-12-05

Similar Documents

Publication Publication Date Title
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
TNSN07240A1 (en) Compounds for flaviviridae treatment
MY139124A (en) Gyrase inhibitors and uses thereof
ZA200701629B (en) Gyrase inhibitors and uses thereof
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
EP2452935A3 (fr) Dérivés de tétracycline pour le traitement d'infections bactériennes, virales et parasites
AP2007004245A0 (en) Compounds and methods for the treatment or prevention of flavivirus infections
SG163517A1 (en) Antiviral compounds and methods
MX2010002318A (es) Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
TW200626157A (en) HCV inhibiting bi-cyclic pyrimidines
DK1419154T3 (da) Rapamycin-29-enoler
MY164469A (en) Hcv ns3 protease inhibitors
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
WO2006024018A3 (fr) Methodes et compositions pour le traitement de la douleur nociceptive
MY145074A (en) Thiazolidin-4-one derivatives
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
WO2006116221A3 (fr) Nouvelles combinaisons therapeutiques pour le traitement ou la prevention de troubles psychotiques
WO2007109105A3 (fr) Inhibition des flavivirus par des sultames et composes apparentes
MY144318A (en) Methods of treating hiv infection.
TW200630367A (en) Substituted adenines and the uses thereof
TN2009000135A1 (en) Use of modified cyclosporins
MXPA05010388A (es) Dispositivos, metodos y composiciones para prevenir la restenosis.
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
WO2009067225A3 (fr) Peptides pour le traitement d'infections par le vhc
SI1838716T1 (sl) Olanzapin pamoat dihidrat